We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Challenges and solutions in the manufacturing and widespread clinical adoption of CAR T-cell therapies.
- Authors
Major, Matthew Charles; Sekhon, Amardeep S.; Michaels, Yale
- Abstract
Chimeric Antigen Receptor (CAR) T-cell therapies are a relatively new addition to our arsenal of treatments against various hematological malignancies and have opened up a new frontier in cancer immunotherapy research. Despite the remarkable clinical efficacy of this treatment modality in conditions such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (LBCL), scalability challenges contribute to a high per patient cost and limit its clinical adoption. This commentary provides a brief discussion of the various technical challenges preventing the large-scale adoption of this therapy in the Canadian healthcare system and potential solutions to these obstacles.
- Subjects
DIFFUSE large B-cell lymphomas; T cells; CHIMERIC antigen receptors; HEMATOLOGIC malignancies
- Publication
UBC Medical Journal, 2022, Vol 13, Issue 2, p21
- ISSN
1920-7425
- Publication type
Article